Effect of Various Treatment Modalities on Dendritic Vial Ulcer
试验速览
- 阶段
- 不适用
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- healing of the epithelium
研究概览
简要总结
Eye infection is a prevalent problem in primary care and remains a crucial healthcare concern. According to the American Academy of Ophthalmology (AAO), herpes simplex virus (HSV) keratitis (HSK) is the leading cause of infectious blindness worldwide . HSK is defined as a corneal inflammatory condition caused by the HSV infection . The global incidence of herpetic keratitis is estimated at 1.5 million per year, resulting in 40,000 new cases of severe visual impairment associated with corneal scarring and opacification . HSV type I (HSV-1) is by far the most predominant causative pathogen of eye infections]. HSV-1 is also known for causing orolabial herpes, HSV folliculitis, herpes gladiatorum, herpetic whitlow, and eczema herpeticum . HSV can be transferred to the eye by touching an active lesion and then the eye. The National Health and Nutrition Evaluation revealed a seroprevalence of HSV-1 in 53.9% of 14-49 year olds, and 90% of adults 50 years or older , indicating that the majority of the population has been exposed to this virus thus are at risk of developing HSK.
In this study we evaluate the efficacy of different treatment modalities on viral keratitis HSK.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients with epithelial viral ulcers
排除标准
- •patients with stromal keratitis patients with corneal opacity
研究组 & 干预措施
group 1'
patients with viral ulcers will receive antiviral medication with antibiotics
干预措施: Acyclovir (Drug)
group 1'
patients with viral ulcers will receive antiviral medication with antibiotics
干预措施: Tobramycin (Drug)
group 2
patients with viral ulcers will receive antiviral medication, tear substitutes with antibiotics
干预措施: Acyclovir (Drug)
group 2
patients with viral ulcers will receive antiviral medication, tear substitutes with antibiotics
干预措施: Tobramycin (Drug)
group 2
patients with viral ulcers will receive antiviral medication, tear substitutes with antibiotics
干预措施: Sodium Hyaluronate (Drug)
group 3
patients with viral ulcers will receive antiviral medication, weak steroids(at the same time) with antibiotics
干预措施: Acyclovir (Drug)
group 3
patients with viral ulcers will receive antiviral medication, weak steroids(at the same time) with antibiotics
干预措施: Tobramycin (Drug)
group 3
patients with viral ulcers will receive antiviral medication, weak steroids(at the same time) with antibiotics
干预措施: Fluorometholone (Drug)
group 4
patients with viral ulcers will receive antiviral medication with antibiotics followed by weak steroid after epithelial healing
干预措施: Acyclovir (Drug)
group 4
patients with viral ulcers will receive antiviral medication with antibiotics followed by weak steroid after epithelial healing
干预措施: Tobramycin (Drug)
group 4
patients with viral ulcers will receive antiviral medication with antibiotics followed by weak steroid after epithelial healing
干预措施: Fluorometholone (Drug)
结局指标
主要结局
healing of the epithelium
时间窗: 10 days follow up
the epithelial healing assessed with flourescin stain and measured by slit lamp scale in millimetres and compared with pre treatment epithelial defect
次要结局
未报告次要终点
研究者
Hany Mahmoud,MD
principal investigator
Sohag University
